A cost-effectiveness analysis of MMX mesalazine compared with mesalazine in the treatment of mild-to-moderate ulcerative colitis from a UK perspective

Abstract Objectives: To perform a cost-utility analysis of a new formulation of mesalazine (Mezavant XL, MMX mesalazine) versus an existing oral mesalazine (Asacol; mesalazine) from the UK National Health Service perspective. Methods: A 5-year Markov cohort model was developed. Costs were obtained f...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of medical economics 2010-03, Vol.13 (1), p.148-161
Hauptverfasser:	Brereton, Nic, Bodger, Keith, Kamm, Michael A., Hodgkins, Paul, Yan, Songkai, Akehurst, Ron
Format:	Artikel
Sprache:	eng
Schlagworte:	Anti-Inflammatory Agents, Non-Steroidal - economics Anti-Inflammatory Agents, Non-Steroidal - therapeutic use Colitis, Ulcerative - drug therapy Colitis, Ulcerative - economics Colitis, Ulcerative - psychology Confidence Intervals cost effectiveness Cost-Benefit Analysis Economics, Pharmaceutical Health Status Indicators Humans Markov Chains Mesalamine - economics Mesalamine - therapeutic use mesalazine Models, Economic Models, Statistical Quality of Life Quality-Adjusted Life Years Severity of Illness Index Time ulcerative colitis Uncertainty United Kingdom
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!